DaTscan: Clinical Trials

2 trials of DaTscan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Terminated 1

Follow DaTscan: new trials by email Literature Review of DaTscan trials Research Report on DaTscan

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Diagnostic Imaging for Clear Cell Renal Cell Carcinoma
Ioflupane I123 - Clear Cell Renal Cell Carcinoma
Phase 2TerminatedRegion Skane52017-07-142019-06-21
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression
DaTscan - Parkinson Disease
Phase 2CompletedKen Marek, MD9522010-06-012023-11-14

Conditions studied

Carcinoma, Renal Cell (1)  ·  Disease (1)  ·  Neurodegenerative Diseases (1)  ·  Parkinson Disease (1)

Sponsors

Ken Marek, MD (1)  ·  Region Skane (1)

Countries

Australia (1)  ·  Austria (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Israel (1)  ·  Italy (1)  ·  Norway (1)  ·  Spain (1)  ·  Sweden (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Andrew Singleton, PhD (1)  ·  Arthur W. Toga, PhD (1)  ·  Christopher Coffey, PhD (1)  ·  John P Seibyl, MD (1)  ·  John Q. Trojanowski, MD, PhD (1)  ·  Karl Kieburtz, MD (1)  ·  Kenneth L Marek, MD (1)  ·  Peter Elfving, M.D. PhD (1)  ·  Tatiana Froud, PhD (1)

Results publications

PMID 25710187, PMID 26534930, PMID 28958801, PMID 28986467, PMID 31678032, PMID 32073681, PMID 33790041, PMID 36849448, PMID 37332638, PMID 37451695, PMID 37491235, PMID 37586882, PMID 38169864, PMID 39043465, PMID 39627057, PMID 39644799, PMID 40164470, PMID 40705614, PMID 41094519, PMID 41453126, PMID 42393590

NIH funding

2016 (1)